Zirconium Zr 89 Cetuximab

Known as: Cetuximab-Zirconium-89, Cetuximab-Zr-89, Zirconium-89-Labeled Cetuximab 
A radioimmunoconjugate comprised of the recombinant chimeric monoclonal antibody cetuximab labeled with the radioisotope zirconium Zr 89 (Zr 89) with… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2017
05101519982017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
PURPOSE Positive margins dominate clinical outcomes after surgical resections in most solid cancer types, including head and neck… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Malignant gliomas remain aggressive and lethal primary brain tumors in adults. The epidermal growth factor receptor (EGFR) is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
The use of receptor-targeted antibodies conjugated to fluorophores is actively being explored for real-time imaging of disease… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Though various targets have been proposed and evaluated, no agent has yet been investigated in a clinical setting for head and… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2011
2011
PURPOSE To assess the rate of serious (>Grade 2, CTCAE 3.0) dermatitis in our head-and-neck cancer (HNC) patients undergoing… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
Cetuximab is a recombinant, human/mouse chimeric IgG1 monoclonal antibody that binds to the epidermal growth factor receptor… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2008
2008
PURPOSE To determine the optimal doses of the antiepidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab and… (More)
Is this relevant?
2007
2007
Photochemical internalization (PCI) is a novel technology of macromolecular delivery. By PCI, endocytosed membrane-impermeable… (More)
Is this relevant?
2006
2006
3509 Background: FOLFIRI or FOLFOX are 1st-line treatments (Rx) for MCRC. Cetuximab is an IgG1 Mab that targets the epidermal… (More)
Is this relevant?
2003
2003
Antibody-PET imaging might be of value for the selection of radioimmunotherapy (RIT) candidates to confirm tumor targeting and to… (More)
Is this relevant?